BOSTON (MarketWatch) — Cephalon Inc said early Monday that it plans to submit an additional market application with U.S. regulators during the third quarter of this year to have its product Nuvigil approved to treat sleepiness associated with jet lag.
Cephalon Inc. said Monday it hopes to ask the Food and Drug Administration to approve Nuvigil as a treatment for jet lag by the third quarter.
The drug is already approved to treat several sleep disorders and is an updated version of Provigil, which also treats sleep disorders.
As part of its drive to cut health-care costs, the Obama administration wants to stop the payments pharmaceutical companies make to generic-drug makers to delay the launch of cheap copies.
Democratic lawmakers have talked about passing legislation to outlaw such deals, and President Barack Obama has vowed to stop the deals in his budget. A House [...]
Its little wonder that when British Home Secretary Jacqui Smith announced to the world that cannabis user figures were in a gentle but perceptible rise, she knew exactly what she was talking about, and was absolutely sure of her facts.
Apparently, offender numbers have shown a marked rise over the last four years even though according [...]